Effectiveness and Safety of PD-1 Inhibitors’ Treatment for Patients with Non-Small-Cell Lung Cancer in China: A Real-World Study

Table 4

Univariate and multivariate analysis of OS in patients treated with immune checkpoint inhibitors.

Baseline characteristics	Median OS (95% CI)	value (univariate analysis)	HR (95% CI)	value (multivariate analysis)
Ages (years)		0.944
<65	30.10 (17.525–42.675)
≥65	28.60 (20.881–36.319)
Sex		0.454
Male	30.50 (21.816–39.184)
Female	28.60 (17.757–39.443)
Therapy lines		0.643
First-line	30.10 (22.787–37.413)
Second or more-line	No reached
Smoking history		0.067
Current or ex-smoker	24.60 (14.752–34.448)		1.753 (0.922–3.333)	0.087
Never-smoker	30.10 (27.538–32.662)
Histology		0.166
Nonsquamous	28.60 (22.304–34.896)
Squamous	30.10 (20.205–39.995)
Pathological staging		0.323
III	30.10 (18.009–42.191)
IV	28.60 (22.700–34.500)
Presence of treating with antibiotic during immunotherapy		0.622
Yes	28.60 (22.352–34.848)
No	30.10 (18.092–42.108)
Presence of serious AEs		0.014
Yes	24.50 (17.013–31.987)		2.199 (1.130–4.280)	0.020
No	30.10 (27.487–32.713)
Presence of irAEs		0.839
Yes	24.60 (19.453–29.747)
No	30.10 (27.698–32.502)